Kavach Boost for Kernex

$KERNEX Kernex Microsystems is emerging as a key beneficiary of India’s railway safety push, but the stock has already moved sharply, so shareholders must weigh strong growth against valuation risk. The company stands among the three patented KAVACH players, and its order book gives strong visibility, yet the upside is not without execution pressure. KAVACH pipeline may be worth about ₹50,000 crore, which could support years of orders for rail-safety suppliers. For Kernex, the big attraction is its strong positioning in the indigenous Train Collision Avoidance System market, where entry barriers are high and the customer is Indian Railways. Financially, the turnaround is clear. CARE Ratings noted that Kernex’s consolidated revenue rose from ₹19.60 crore in FY24 to ₹189.88 crore in FY25, while PAT improved from a loss of ₹26.71 crore to a profit of ₹50.05 crore; Q1 FY26 revenue was ₹55.93 crore with PAT of ₹7.41 crore. Later market reports showed Q4 FY26 revenue at ₹254.58 crore and net profit at ₹68.26 crore, with full-year FY26 revenue at ₹430.22 crore and profit at ₹88.24 crore. The order book is another major support. CARE reported an outstanding order book of ₹2,563 crore as of September 30, 2025, including a ₹1,730 crore order for 2,500 Loco TCAS units, while newer market updates placed the order book around ₹4,150 crore. For shareholders, this is beneficial if execution stays on track because higher revenue, better profits, and a deep order pipeline can keep earnings rising. The risk is that the business is tender-driven, tied heavily to Indian Railways, and working-capital intensive, with CARE flagging an operating cycle of 171 days in FY25 and concentrated order dependence. At current levels, the stock looks like a quality growth story rather than a cheap one. The benefit to shareholders is strong earnings momentum; the detriment is that any delay in Kavach rollout, pricing pressure, or valuation cooling can hit returns fast.